When was TauRx founded?

TauRx was founded in 2002 and became a unicorn in 2018, reaching the milestone in 16 years. It raised its 1st funding round 9 years after its incorporation.

Where is TauRx located?

TauRx is headquartered in Singapore, Singapore. It is registered at SHENTON WAY Pincode : 68805.

Who is the current CEO of TauRx?

Claude Wischik of TauRx. They have also founded 1 company.

Which legal entities is TauRx associated with?

TauRx is associated with TauRx Pharmaceuticals Ltd. and 1 other.

How many employees does TauRx have?

As of Mar 01, 2026, the latest employee count at TauRx is 50 - 199.

Is TauRx a funded company?

TauRx is a funded company, having raised a total of $434M across 6 funding rounds to date. The company's 1st funding round was a $20M Series A round, raised on Sep 2011.

How much is TauRx worth?

The latest valuation of TauRx is $2.5B as of Mar 02, 2018.

When was the latest funding round of TauRx?

TauRx's latest funding was a $119M Series E round on Nov 14, 2022, with participation from 0 investor.

What is the annual revenue of TauRx?

Annual revenue of TauRx is less than $1M as on Jun 30, 2024

Is TauRx a Neurology company?

The primary sector of TauRx is Neurology.

Where does TauRx rank among its competitors?

TauRx ranks 130th amongst 457 active competitors, of which 161 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Mission Therapeutics, which secured $13.3M in Oct, 2025.

Who are the top competitors of TauRx?

TauRx's top competitors include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Among them, Mission Therapeutics secured the most recent funding round in October, 2025.

TauRx - 2026 Company Profile, Team, Funding, Competitors & Financials

TauRx is a series E company based in Singapore (Singapore), founded in 2002 by Claude Wischik and K M Seng. It operates as a Developer of treatments for neurodegenerative diseases. TauRx has raised $434M in funding from Dundee Corporation and Genting Singapore, with a current valuation of $2.5B. The company has 457 active competitors, including 161 funded and 82 that have exited. Its top competitors include companies like Denali Therapeutics, Fulcrum Therapeutics and Regenxbio.

Sectors and market segments that TauRx operate in

TauRx serves in the Life Sciences market segments.The primary business model of TauRx is:

Life Sciences > Neurology > ***** **** > ***** ******

Company Details

Developer of treatments for neurodegenerative diseases, specifically Alzheimer's disease and frontotemporal dementia. The company focuses on the development and commercialization of treatments targeting tau pathology. Research and development efforts include clinical trials and collaborations to advance therapeutic options. The company's pipeline includes a drug candidate currently under regulatory review for mild cognitive impairment and mild to moderate Alzheimer's disease.

Website: taurx.com
Social
Registered Address: SHENTON WAY Pincode : 68805

Key Metrics

Founded Year

2002

Location

Singapore, Singapore

Stage

Series E

Total Funding

$434M in 6 rounds

Latest Funding Round

Series E, Nov 14, 2022, $119M

Post Money Valuation

$2.5B as on Mar 02, 2018

Investors

Dundee Corporation & 110 more

Ranked

130^th among 457 active competitors

Annual Revenue

$0 - $1M as on Jun 30, 2024

Employee Count

50 - 199 as on Mar 01, 2026

Similar Companies

Denali Therapeutics & 567 more

View TauRx's full profile

TauRx is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
TAURX PHARMACEUTICALS LTD. CIN: 200803885H , Singapore, Active	Sep 12, 2008	$0 - $1M (As on Jun 30, 2024)	-
TauRx Pharmaceuticals Ltd. CIN: 200803885H , Singapore, Active	Mar 04, 2013	-	-

TauRx has raised a total funding of $434M over 6 rounds. Its first funding round was on Sep 2011. TauRx has 50 institutional investors and 61 angel investors.

Here is the list of recent funding rounds of TauRx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 14, 2022	$119M	Series E	-	-	-	-
Jul 27, 2016	$118M	Series D	-	-	-	-
Oct 07, 2015	$135M	Series D	-	-	-	-

Access funding benchmarks and valuations. Sign up today!

View details of TauRx's funding rounds and investors

The founders of TauRx are Claude Wischik and K M Seng. Claude Wischik is the CEO of TauRx.

Here are the details of TauRx's key team members:

Claude Wischik: Co-Founder & CEO of TauRx.
K M Seng: Co-Founder of TauRx.

TauRx's Board of Directors

TauRx's board has 17 active members. Claude Michel Wischik is part of team and Seng Shay Way, Loh Yin Sze, Lin Daqi, Michael Thomas Dudley Cooper, Cheng Teck Heng Paul, Chia Peng Soon George, Tan Kong Han, Goh Lee Sian, Lim Kit Li, Vasoo Sushilan, Han Kwang, Tang Jialei, Siew Choon Tay, Lim Kok Thay, Chung Goh and Marcus Augustine Wischik are independent board members.

Here is the list of TauRx's board of directors:

Name	Type	Representing	Status	Duration
Claude Michel Wischik	Team	-	Current	17y 4m
Seng Shay Way	Independent board member	-	Current	16y 3m
Loh Yin Sze	Independent board member	-	Current	16y 3m
Lin Daqi	Independent board member	-	Current	2y 4m
Michael Thomas Dudley Cooper	Independent board member	-	Current	1y 2m
Cheng Teck Heng Paul	Independent board member	-	Current	10y 2m
Chia Peng Soon George	Independent board member	-	Current	16y 3m
Tan Kong Han	Independent board member	-	Current	13y 7m
Goh Lee Sian	Independent board member	-	Current	13y 7m
Lim Kit Li	Independent board member	-	Current	1y 6m
Vasoo Sushilan	Independent board member	-	Current	16y 3m
Han Kwang	Independent board member	-	Current	1y 3m
Tang Jialei	Independent board member	-	Current	2y 4m
Siew Choon Tay	Independent board member	-	Current	17y 11m
Lim Kok Thay	Independent board member	-	Current	13y 7m
Chung Goh	Independent board member	-	Current	16y 3m
Marcus Augustine Wischik	Independent board member	-	Current	14y 9m
Jean Wan Yen-ping	Independent board member	-	Past	0y 4m
Cheng Teng Wei Lionel	Independent board member	-	Past	1y 6m
Woon Yoke Sun	Independent board member	-	Past	12y 1m
Yap Lune Teng	Independent board member	-	Past	0y 4m
Tan Lee Yian Joan	Independent board member	-	Past	4y 10m
Chua Shih Guan	Independent board member	-	Past	4y 0m
Timothy Mark Toby O' Connor	Independent board member	-	Past	3y 5m
Chen Huaidan	Independent board member	-	Past	3y 6m
Stephen D Logan	Independent board member	-	Past	15y 9m
Frederick Stevenson-robb	Independent board member	-	Past	15y 9m

View details of TauRx's Founder profiles and Board Members

TauRx's employee count trend

TauRx has 50 - 199 employees as of Mar 26. Here is TauRx's employee count trend over the years:

Uncover TauRx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of TauRx include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Here is the list of Top 10 competitors of TauRx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
3rd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
4th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, New Enterprise Associates ... & 17 others	67/100
5th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	66/100
6th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
7th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, Sanofi & 5 others	65/100
8th	Athira Pharma 2011, Seattle (United States), Public	Developer of drugs for neurodegenerative diseases	$121M	Dolby Family Ventures, Alzheimer's Drug Discovery ... & 22 others	65/100
9th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$115M	RA Capital Management, SV Health Investors ... & 13 others	64/100
10th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Smile Gate Investment, Praxis Capital & 10 others	64/100
130th	TauRx 2002, Singapore (Singapore), Series E	Developer of treatments for neurodegenerative diseases	$434M	Evia Capital Partners, GEM Asset Management ... & 109 others	42/100